Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Economic Impact of Adherence to Pain Treatment Guidelines in Chronic Pain Patients.

Margolis JM, Princic N, Smith DM, Abraham L, Cappelleri JC, Shah SN, Park PW.

Pain Med. 2019 Apr 29. pii: pnz085. doi: 10.1093/pm/pnz085. [Epub ahead of print]

PMID:
31034040
2.

Development of a novel algorithm to determine adherence to chronic pain treatment guidelines using administrative claims.

Margolis JM, Princic N, Smith DM, Abraham L, Cappelleri JC, Shah SN, Park PW.

J Pain Res. 2017 Feb 8;10:327-339. doi: 10.2147/JPR.S118248. eCollection 2017.

3.

Evaluating increased resource use in fibromyalgia using electronic health records.

Margolis JM, Masters ET, Cappelleri JC, Smith DM, Faulkner S.

Clinicoecon Outcomes Res. 2016 Nov 16;8:675-683. eCollection 2016.

4.

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.

Margolis JM, Deitelzweig S, Kline J, Tran O, Smith DM, Bookhart B, Crivera C, Schein J.

J Am Heart Assoc. 2016 Oct 6;5(10). pii: e003788.

5.

Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin.

Margolis JM, Deitelzweig S, Kline J, Tran O, Smith DM, Crivera C, Bookhart B, Schein J.

Clin Ther. 2016 Nov;38(11):2496-2503. doi: 10.1016/j.clinthera.2016.09.007. Epub 2016 Oct 15.

6.

Herpes Zoster-Related Health Care Resource Utilization in Cancer Patients in 5 European Countries.

Gebremeskel BG, Lopez-Gonzalez L, Patwardhan P, Chin J, Schwalm MS, Acosta CJ, Margolis JM.

Value Health. 2014 Nov;17(7):A684. doi: 10.1016/j.jval.2014.08.2555. Epub 2014 Oct 26. No abstract available.

7.

Health care resource utilization and medical costs of spinal cord injury with neuropathic pain in a commercially insured population in the United States.

Margolis JM, Juneau P, Sadosky A, Cappelleri JC, Bryce TN, Nieshoff EC.

Arch Phys Med Rehabil. 2014 Dec;95(12):2279-87. doi: 10.1016/j.apmr.2014.07.416. Epub 2014 Aug 24.

PMID:
25159715
8.

Health care utilization and expenditures among Medicaid beneficiaries with neuropathic pain following spinal cord injury.

Margolis JM, Juneau P, Sadosky A, Cappelleri JC, Bryce TN, Nieshoff EC.

J Pain Res. 2014 Jul 1;7:379-87. doi: 10.2147/JPR.S63796. eCollection 2014.

9.

Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action.

Margolis JM, Chu BC, Wang ZJ, Copher R, Cavazos JE.

JAMA Neurol. 2014 Aug;71(8):985-93. doi: 10.1001/jamaneurol.2014.808.

PMID:
24911669
10.

Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study.

Margolis JM, Fowler R, Johnson BH, Kassed CA, Kahler K.

BMC Neurol. 2011 Oct 6;11:122. doi: 10.1186/1471-2377-11-122.

11.

Outcomes of breast cancer patients with triple negative receptor status treated with accelerated partial breast irradiation.

Wilkinson JB, Reid RE, Shaitelman SF, Chen PY, Mitchell CK, Wallace MF, Marvin KS, Grills IS, Margolis JM, Vicini FA.

Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e159-64. doi: 10.1016/j.ijrobp.2010.12.031. Epub 2011 Feb 23.

PMID:
21345613
12.

Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans.

Margolis JM, Cao Z, Onukwugha E, Sanchez RJ, Alvir J, Joshi AV, Mullins CD.

Am J Manag Care. 2010 Jun;16(6):447-56.

13.

Effects of a Medicaid prior authorization policy for pregabalin.

Margolis JM, Johnston SS, Chu BC, Onukwugha E, Hvidsten K, Alvir J, Rossi JG, Mullins CD.

Am J Manag Care. 2009 Oct 1;15(10):e95-102.

14.

Dominant non-coding repeat expansions in human disease.

Dick KA, Margolis JM, Day JW, Ranum LP.

Genome Dyn. 2006;1:67-83. doi: 10.1159/000092501. Review.

PMID:
18724054
16.

DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression.

Margolis JM, Schoser BG, Moseley ML, Day JW, Ranum LP.

Hum Mol Genet. 2006 Jun 1;15(11):1808-15. Epub 2006 Apr 19.

PMID:
16624843
18.

(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes.

Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS.

Drug Metab Dispos. 2000 Oct;28(10):1187-91.

PMID:
10997938
19.

The tracing of the pathway of mevalonate's metabolism to other than sterols.

Brady PS, Scofield RF, Schumann WC, Ohgaku S, Kumaran K, Margolis JM, Landau BR.

J Biol Chem. 1982 Sep 25;257(18):10742-6.

20.

Pathways of acetoacetate's formation in liver and kidney.

Brady PS, Scofield RF, Ohgaku S, Schumann WC, Bartsch GE, Margolis JM, Kumaran K, Horvat A, Mann S, Landau BR.

J Biol Chem. 1982 Aug 25;257(16):9290-3.

21.

A method for quantitating the contributions of the pathways of acetoacetate formation and its application to diabetic ketosis in vivo.

Ohgaku S, Brady PS, Schumann WC, Bartsch GE, Margolis JM, Kumaran K, Landau SB, Landau BR.

J Biol Chem. 1982 Aug 25;257(16):9283-9.

22.

On the lack of formation of L-(+)-3-hydroxybutyrate by liver.

Scofield RF, Brady PS, Schumann WC, Kumaran K, Ohgaku S, Margolis JM, Landau BR.

Arch Biochem Biophys. 1982 Mar;214(1):268-72. No abstract available.

PMID:
7082002
23.

Quantitation of pathways of ethanol metabolism.

Havre P, Abrams MA, Corrall RJ, Yu LC, Szczepanik PA, Feldman HB, Klein P, Kong MS, Margolis JM, Landau BR.

Arch Biochem Biophys. 1977 Jul;182(1):14-23. No abstract available.

PMID:
883827
24.

Subcellular site of acetaldehyde oxidation in omnkey liver.

Havre P, Margolis JM, Abrams MA.

Biochem Pharmacol. 1976 Dec 15;25(24):2757-8. No abstract available.

PMID:
827297
25.

Stereospecificity of the microsomal ethanol-oxidizing system.

Corrall RJ, Yu LC, Rosner BA, Margolis JM, Rodman HM, Kam W, Landau BR.

Biochem Pharmacol. 1975 Oct 1;24(19):1825-7. No abstract available.

PMID:
9946

Supplemental Content

Loading ...
Support Center